|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-15
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1600-0609
|
|
pubmed:author |
pubmed-author:CakanaAndrewA,
pubmed-author:DeraedtWilliamW,
pubmed-author:DimopoulosMeletios AMA,
pubmed-author:EsseltineDixie-LeeDL,
pubmed-author:KhuagevaNuriet KNK,
pubmed-author:KropffMartinM,
pubmed-author:LiuKevinK,
pubmed-author:MateosMaria-VictoriaMV,
pubmed-author:PalumboAntonioA,
pubmed-author:RichardsonPaul GPG,
pubmed-author:San MiguelJesús FJF,
pubmed-author:SchlagRudolfR,
pubmed-author:ShpilbergOferO,
pubmed-author:SpickaIvanI,
pubmed-author:Van De VeldeHelgiH,
pubmed-author:WuKa LungKL
|
|
pubmed:copyrightInfo |
© 2010 John Wiley & Sons A/S.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
23-31
|
|
pubmed:meshHeading |
pubmed-meshheading:20874823-Aged,
pubmed-meshheading:20874823-Aged, 80 and over,
pubmed-meshheading:20874823-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20874823-Boronic Acids,
pubmed-meshheading:20874823-Female,
pubmed-meshheading:20874823-Humans,
pubmed-meshheading:20874823-Male,
pubmed-meshheading:20874823-Melphalan,
pubmed-meshheading:20874823-Middle Aged,
pubmed-meshheading:20874823-Multiple Myeloma,
pubmed-meshheading:20874823-Multivariate Analysis,
pubmed-meshheading:20874823-Peripheral Nervous System Diseases,
pubmed-meshheading:20874823-Prednisone,
pubmed-meshheading:20874823-Pyrazines,
pubmed-meshheading:20874823-Risk Factors
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
|
|
pubmed:affiliation |
School of Medicine, University of Athens, Athens, Greece. mdimop@med.uoa.gr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
